Le Lézard
Classified in: Environment, Health, Science and technology
Subject: Product/Service

New Strategic Vision for Biotechnology Innovation Organization


The Biotechnology Innovation Organization (BIO) today announced a new, strategic direction that will help guide it to achieving long-term goals while maintaining responsiveness to changing political headwinds.

Announcing the new vision, mission and purpose to member companies, BIO's recently appointed President and CEO, Dr. Michelle McMurry-Heath remarked, "We need to be the face and the voice of science?speaking up for the millions of families around the globe who depend upon our success. That means being bold, memorable, and?at times?provocative. But if we are as proud of our scientists and as committed to our patients and consumers as I know we are, then it is not only the best tactic, it is our duty."

After at least 106 one-on-one conversations with member companies, extensive strategic planning sessions, a broad membership survey and several focus groups, BIO outlined the new direction through

BIO plans to execute on the strategic direction though five different pillars:

  1. Be a voice of science and for science.
  2. Unite and empower biotech innovators and their ecosystem to improve lives.
  3. Remove barriers to innovation.
  4. Champion broad access to biotech breakthroughs and scientific quality.
  5. Catalyze resilient and sustainable bio-based economies.

The Board and staff of the nearly 1000-member organization plan to operationalize the five pillars beginning immediately. For more information on BIO's new strategic direction, visit www.bio.org/strategic-vision.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.


These press releases may also interest you

at 06:50
Merck , known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then...

at 06:31
Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual...

at 06:30
Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular...

at 06:30
The collagen water market is booming thanks to the growing popularity of health and beauty products. Consumers are more interested in skincare and healthy eating, which is driving manufacturers to create collagen-infused drinks and cosmetics. A new...

at 06:30
Viavi Solutions Inc. (VIAVI)  today announced it has participated in the 2024 RIC Forum, March 26-28, in Dallas, Texas. The company contributed its TeraVM RIC Test and TM500 Network Tester to multiple demonstrations, building on collaborations at MWC...

at 06:30
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points  New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively...



News published on and distributed by: